Population Pharmacokinetics And Pharmacodynamics Of Paclitaxel And Carboplatin In Ovarian Cancer Patients: A Study By The European Organization For Research And Treatment Of Cancer-Pharmacology And Molecular Mechanisms Group And New Drug Development Group
This study demonstrated concentration-effect relationships of paclitaxel for both toxicity and outcome in 103 ovarian cancer patients. The relevant pharmacokinetic parameter was time above threshold Tc>0.05. Patients with severe neutropenia (grade 3 – 4) had higher paclitaxel exposure than patients with mild or absent neutropenia (p=0.02). Remission and stable disease compared to progressive disease were both associated with paclitaxel levels (p=0.02 and p=0.05). Patients with higher paclitaxel also had longer time to progression (p=0.03).